TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 33
- +4 vs. Q4 2023
- Portfolio value
- $1.26B
- +$363.2M (+40.3%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 3,570,206 | $156.7M | 12.4% | +3,570,206 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 2,650,150 | $75.2M | 5.9% | +1,000,000+60.6% | Added | History |
| ATXSAstria Therapeutics, Inc. | COM | 5,278,928 | $74.3M | 5.9% | +5,278,928 | New | History |
| SLNSilence Therapeutics plc | ADS | 3,295,350 | $71.2M | 5.6% | +1,190,475+56.6% | Added | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,598,421 | $68.5M | 5.4% | −511,163−24.2% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM | 2,201,274 | $65.1M | 5.1% | 00.0% | Unchanged | History |
| INBXInhibrx Biosciences, Inc. | COM | 1,750,387 | $61.2M | 4.8% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 879,344 | $58.2M | 4.6% | +879,344 | New | History |
| GERNGeron Corp | COM | 17,391,639 | $57.4M | 4.5% | −5,984,200−25.6% | Reduced | History |
| SVRASavara Inc | COM | 10,000,000 | $49.8M | 3.9% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 5,319,148 | $48.4M | 3.8% | +5,319,148 | New | History |
| COGTCogent Biosciences, Inc. | COM | 6,214,375 | $41.8M | 3.3% | +583,333+10.4% | Added | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 2,272,728 | $41.5M | 3.3% | +2,272,728 | New | History |
| MLYSMineralys Therapeutics, Inc. | COM | 3,185,185 | $41.1M | 3.3% | +3,185,185 | New | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 149,283 | $39.9M | 3.2% | −30,634−17.0% | Reduced | History |
| TRMLTourmaline Bio, Inc. | COM | 1,477,593 | $33.8M | 2.7% | +469,691+46.6% | Added | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $32.6M | 2.6% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $32.1M | 2.5% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $30.4M | 2.4% | 00.0% | Unchanged | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 793,829 | $28.9M | 2.3% | −349,028−30.5% | Reduced | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 2,008,340 | $28.4M | 2.2% | +2,008,340 | New | History |
| SLNOSoleno Therapeutics Inc | COM NEW | 550,000 | $23.5M | 1.9% | +550,000 | New | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,040,816 | $23.1M | 1.8% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,100,000 | $15.7M | 1.2% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 2,676,580 | $14.1M | 1.1% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,163,356 | $13.8M | 1.1% | −2,232,139−65.7% | Reduced | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,276,574 | $10.4M | 0.8% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $8.29M | 0.7% | 00.0% | Unchanged | History |
| ANTXAN2 Therapeutics, Inc. | COM | 1,555,118 | $5.05M | 0.4% | −1,123,091−41.9% | Reduced | History |
| KODKodiak Sciences Inc. | COM | 899,999 | $4.73M | 0.4% | +632,058+235.9% | Added | History |
| VTYXVentyx Biosciences, Inc. | COM | 815,724 | $4.49M | 0.4% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM | 4,000,000 | $3.74M | 0.3% | +4,000,000 | New | History |
| CABACabaletta Bio, Inc. | COM | 86,795 | $1.48M | 0.1% | −400,000−82.2% | Reduced | History |
Sold out since Q4 2023 (5)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| ICVXIcosavax, Inc. | COM | 3,703,704 | $58.4M | 6.5% | History |
| RYZBRayzeBio, Inc. | COM | 869,908 | $54.1M | 6.0% | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 4,514,786 | $45.3M | 5.0% | – |
| NRIXNurix Therapeutics, Inc. | COM | 717,654 | $7.41M | 0.8% | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 2,912,861 | $5.16M | 0.6% | History |